Volume 5.39 | Oct 3

Mammary Cell News 5.39 October 3, 2013
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
CD95L Cell Surface Cleavage Triggers a Pro-Metastatic Signaling Pathway in Triple Negative Breast Cancer
Scientists report that serum levels of CD95L are higher in triple negative breast cancer patients compared to other breast cancer patients. [Cancer Res] Abstract
Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response
PUBLICATIONS (Ranked by impact factor of the journal)

Profiles of Basal and Stimulated Receptor Signaling Networks Predict Drug Response in Breast Cancer Lines
Scientists profiled signaling pathway activity in a collection of breast cancer cell lines before and after stimulation with physiologically relevant ligands, which revealed the variability in network activity among cells of known genotype and molecular subtype. [Sci Signal] Abstract

Cell Type-Dependent Pathogenic Functions of Overexpressed Human Cathepsin B in Murine Breast Cancer Progression
In order to evaluate the impact of tumor- or stromal cell-derived cysteine protease cathepsin B (CTSB) on Polyoma Middle T (PyMT)-induced breast cancer progression, investigators used in vivo and in vitro approaches to induce human CTSB overexpression in PyMT cancer cells or stromal cells alone or in combination. [Oncogene] Abstract

Metastasis Tumor-Associated Protein 2 Enhances Metastatic Behavior and Is Associated with Poor Outcomes in Estrogen Receptor-Negative Breast Cancer
Researchers hypothesized that metastasis tumor-assigned protein 2 (MTA2) enhances breast cancer progression. To test this, cell growth, soft-agar colony formation, migration, and in vivo metastasis were examined in MTA2-overexpressing and Vector control transfected estrogen receptor α-negative breast cancer cells. [Breast Cancer Res Treat] Abstract

Low Molecular Weight Protein Tyrosine Phosphatase Isoforms Regulate Breast Cancer Cells Migration Through a RhoA Dependent Mechanism
Low molecular weight protein tyrosine phosphatase (LMW-PTP) has been associated with cell proliferation control through dephosphorylation and inactivation of growth factor receptors such as platelet derived growth factor receptor and Ephrin Receptor A2, and with cellular adhesion and migration through p190RhoGap and RhoA. Investigators aimed to clarify the role of two main LMW-PTP isoforms in breast cancer tumorigenesis. [PLoS One] Full Article

Herbacetin, a Constituent of Ephedrae Herba, Suppresses the HGF-Induced Motility of Human Breast Cancer MDA-MB-231 Cells by Inhibiting c-Met and Akt Phosphorylation
Authors report that herbacetin suppressed hepatocyte growth factor-induced motility in human breast cancer MDA-MB-231 cells by inhibiting c-Met and Akt phosphorylation and directly inhibiting c-Met tyrosine kinase activity. [Planta Med] Abstract


Phase I Trial of the Oral PARP Inhibitor Olaparib in Combination with Paclitaxel for First- or Second-Line Treatment of Patients with Metastatic Triple-Negative Breast Cancer
This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral Poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with paclitaxel in patients with metastatic triple-negative breast cancer. [Breast Cancer Res]
| Full Article

Elevated Levels of Serum Tumor Markers CA 15-3 and CEA Are Prognostic Factors for Diagnosis of Metastatic Breast Cancers
After primary treatments of locoregional breast cancers, serum cancer antigen (CA) 15-3 and/or carcinoembryonic antigen (CEA) concentrations were regularly measured, and systemic recurrences were identified in 351 patients between January 1999 and December 2009. The association between tumor marker levels at systemic recurrence and survival were investigated by univariate and multivariate analyses. [Breast Cancer Res Treat] Abstract

Phase I-II Study of the Farnesyl Transferase Inhibitor Tipifarnib Plus Sequential Weekly Paclitaxel and Doxorubicin-Cyclophosphamide in HER2/Neu-Negative Inflammatory Carcinoma and Non-Inflammatory Estrogen Receptor-Positive Breast Carcinoma
Tipifarnib (T) is a farnesyl transferase inhibitor that enhances the antineoplastic effects of cytotoxic therapy in vitro, has activity in metastatic breast cancer, and enhances the pathologic complete response rate to neoadjuvant doxorubicin-cyclophosphamide (AC) chemotherapy. Investigators, therefore, performed a phase I-II trial of T plus neoadjuvant sequential weekly paclitaxel and 2-week AC chemotherapy in locally advanced breast cancer. [Breast Cancer Res Treat] Abstract

[Free On-Demand Webinar] Potential Applications of ALDH+ Cells in Regenerative Medicine - Watch Now.
Immunotherapeutics for Breast Cancer
Authors review recent advances leading to a new understanding of immunology of breast cancer with its potential clinical applications. [Curr Opin Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Etubics Awarded $1.5 Million Manufacturing Contract for Breast Cancer Immunotherapeutic
Etubics Corporation announced that it has received a contract of approximately $1.5 million from Small Business Innovation Research (SBIR) Development Center of the National Cancer Institute (NCI) to manufacture Etubics’ breast cancer immunotherapeutic, ETBX-021. [Etubics Corporation] Press Release

FDA Grants Roche’s Perjeta Accelerated Approval for Use Before Surgery in People with HER2-Positive Early Stage Breast Cancer
Roche announced that the United States Food and Drug Administration (FDA) granted accelerated approval of a Perjeta (pertuzumab) regimen for neoadjuvant treatment in people with high-risk, HER2-positive early stage breast cancer. [F. Hoffman-La Roche Ltd] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.
US Government Shuts Down
The US government entered a state of suspended animation on 1 October after Congress failed to agree on a budget for the next fiscal year, causing federal agencies – including those overseeing science policy and research – to shut down indefinitely. Most government scientists were ordered to stay at home, their offices and labs closed or run by a skeleton staff of ‘essential’ workers. The National Institutes of Health and the National Science Foundation stopped processing grants, some government websites were made inaccessible and many important research programmes were left hanging, potentially putting lives at risk in the case of some disease studies. [Nature News] Editorial

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 3rd Asia-Pacific Breast Cancer Summit
February 22-23, 2014
Singapore, Singapore

NEW Methods in Clinical Cancer Research
June 21-27, 2014
Flims, Switzerland

NEW Australia and Asia Pacific Clinical Oncology Research Development Workshop
September 14-20, 2014
Sunshine Coast, Australia

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Position – Computational Biology of Cancer (Gustave Roussy Cancer Institute)

NEW Postdoctoral Position – Triple Negative Breast Cancer (Weizmann Institute of Science)

NEW Postdoctoral Fellow – Nutritional Cancer Epigenetics (Purdue University)

PhD Position – Breast Cancer Bone Metastasis Formation (Claude Bernard University Lyon 1)

Faculty Position – Management/Research of Hematologic, Breast, Head and Neck, Gastrointestinal, and Thoracic Medicine (Vanderbilt University Medical Center)

Vice President, Global Medical Affairs Position – Breast Disease (Celgene Corporation)

Postdoctoral Fellow – Breast Cancer Biology (Stephenson Cancer Center at the University of Oklahoma)

Research Assistant – Cellular Pathways Involved in Oncogenic Transformation of Breast Epithelial Cells (Mount Sinai School of Medicine)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Postdoctoral Fellow in Breast Cancer – (Bellvitge Biomedical Research Institute [IDIBELL])

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Technologist – Mesenchymal Cell Research (STEMCELL Technologies Inc.)

Research Technologist – Cell Culture Media & Matrices (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Quality Control Analyst – Media (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Mammary Cell News: Archives | Events | Contact Us